---
title: Crux Biolabs vs PPD
slug_a: cruxbiolabs
slug_b: ppd
site: cro
review_signal_gate: closed
canonical_path: /compare/cruxbiolabs/ppd
---

# Crux Biolabs vs PPD

Side-by-side profile data from each company listing on this directory.

## Crux Biolabs

- Profile: [/companies/cruxbiolabs](/companies/cruxbiolabs)

Crux Biolabs — Australia-based bioanalytical CRO offering small molecule LC-MS PK, ligand-binding large molecule PK, immunogenicity (ADA), biomarker, and flow cytometry assays for clinical programs. Services are delivered within an ISO/IEC 17025-accredited scope where applicable.

Services: 6. Modalities: 4. Indications: 4. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in services (6).

### Services

- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services

### Modalities

- Small Molecule
- Biologics (Other)
- Cell Therapy
- Vaccine

### Indications

- Oncology
- Immunology
- Metabolic
- Infectious Disease

### Phases

- Data not yet provided.

### Sourcing models

- Data not yet provided.

## PPD

- Profile: [/companies/ppd](/companies/ppd)

PPD — PPD is a leading global contract research organization (CRO) and the clinical research business of Thermo Fisher Scientific.

Services: 19. Modalities: 6. Indications: 14. Locations: 9. Certifications: 0. The strongest documented coverage currently appears in services (19).

### Services

- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Biomarker Assays
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Pharmacovigilance & Drug Safety
- Medical Writing
- Central Laboratory Services
- Clinical Imaging Core Lab
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Cell Therapy
- Gene Therapy
- Vaccine

### Indications

- Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health

### Phases

- Phase II
- Phase III
- Phase IV
- Real-World Evidence (RWE) / Registries

### Sourcing models

- Full-Service Outsourcing (FSO)
- Functional Service Provider (FSP)